Structures and inhibition of the Crimean-Congo haemorrhagic fever virus polymerase.
Xue, L., Gui, J., Pan, H., Wu, F., Gao, S., Kuang, W., Chang, T., Li, Z., Zou, B., Zhao, H., Li, M., Zhou, M., Yuan, H., Rong, L., Gong, P., He, J., Deng, Z., Wang, M., Zhan, P., Chen, X., Xiong, X.(2026) Nature 
- PubMed: 42486991 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41586-026-10701-6
- Primary Citation Related Structures: 
9XD4, 9XD5, 9XD6, 9XE6, 9XE7, 9XE9, 9XEC, 9XF9 - PubMed Abstract: 
Crimean-Congo haemorrhagic fever virus (CCHFV) is a tick-borne virus and causes severe, often fatal, human infections. Lacking licensed vaccines or drugs, CCHFV is a World Health Organization priority pathogen requiring urgent development of medical countermeasures 1,2 . The CCHFV Large (L) protein functions as the viral RNA-dependent RNA polymerase CCHFV-L, representing a promising antiviral target, and is among the largest viral polymerases in the order Bunyavirales. Here we define the cofactors required for CCHFV-L RNA synthesis in vitro, enabling capture and determination of elongating CCHFV-L-RNA complex structures. The structures show a markedly enlarged polymerase architecture, revealing that CCHFV-L RNA synthesis is accompanied by ordering of the polymerase peripheral domains. We also define how the baloxavir-derived experimental drug WXSH0208 (ref. 3 ) and the nucleoside analogue 2'-deoxy-2'-fluorocytidine 4,5 , which has nanomolar cellular potency, inhibit this polymerase through endonuclease inhibition and post-translocation chain termination, respectively. Together, these results should structurally guide rational optimization of inhibitors directed against CCHFV-L.
- State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Organizational Affiliation: 


















